









Markets
/
Stocks
/
nasdaq-srpt
/

Sarepta Therapeutics Inc

SRPT



View Detailed Chart

21.310USD

+0.270+1.28%

Market hours （ET）Quotes delayed by 15 min

2.23BMarket Cap

LossP/E TTM



Sarepta Therapeutics Inc

21.310

+0.270+1.28%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+1.28%

5 Days

-1.02%

1 Month

+20.46%

6 Months

+6.13%

Year to Date

-82.47%

1 Year

-82.09%

View Detailed Chart

TradingKey Stock Score of Sarepta Therapeutics Inc

Currency: USD Updated: 2025-12-19

Key Insights

Sarepta Therapeutics Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 90/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 29.46.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Sarepta Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

90 / 158

Overall Ranking

225 / 4582

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 28 analysts

Hold

Current Rating

29.457

Target Price

+34.75%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Sarepta Therapeutics Inc Highlights

StrengthsRisks

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 103.85% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is -7.79, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 84.30M shares, decreasing 20.58% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 11.84K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 2.36.

Sarepta Therapeutics Inc News

Sarepta Surges Over 14% as FDA Lifts Shipping Ban; Wall Street Anticipates Doubling in Stock Price

TradingKey - Sarepta Therapeutics (SRPT.US) announced on Monday, July 28, that it has resumed shipments of its gene therapy Elevidys in the U.S., following an authorization from the U.S. Food and Drug Administration (FDA). The company's stock spiked over 20% on Tuesday, closing up 14.21% at $15.83,

TradingKeyWed, Jul 30